<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124355</url>
  </required_header>
  <id_info>
    <org_study_id>6111</org_study_id>
    <nct_id>NCT03124355</nct_id>
  </id_info>
  <brief_title>Vagal Stimulation in POTS</brief_title>
  <official_title>Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how the electrical stimulation of a nerve in the&#xD;
      skin of the earlobe (transcutaneous vagal nerve stimulation), alone or in combination with&#xD;
      two medications (galantamine and pyridostigmine), affects the way the autonomic (involuntary)&#xD;
      nervous system controls heart rhythm, symptoms on standing, and inflammatory markers in&#xD;
      female patients with postural tachycardia syndrome (POTS). The study consists of 2 parts: a&#xD;
      screening (1-2 study days), and 3 testing days. The study will take 5 days total and about 16&#xD;
      participants will be screened for the study. The investigators estimate 13 will be eligible&#xD;
      to participate in all of the study days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that impairment of the parasympathetic nervous system&#xD;
      contributes to the symptoms of POTS and that stimulation of this part of the nervous system&#xD;
      improves the excessive increase in heart rate, standing tolerance and inflammation in&#xD;
      patients with POTS. For this purpose, the investigators will use electrical stimulation of a&#xD;
      nerve in the skin of the earlobe (transcutaneous vagal nerve stimulation) and two medications&#xD;
      that increase the levels of acetylcholine (a neurotransmitter) in the central or peripheral&#xD;
      nervous system (galantamine and pyridostigmine, respectively) to increase the activity of the&#xD;
      parasympathetic nervous system.&#xD;
&#xD;
      Screening Procedures: Potential participants will be screened in the Vanderbilt Autonomic&#xD;
      Dysfunction Center (ADC). Medications affecting heart rate, blood pressure, blood volume,&#xD;
      inflammatory markers and the autonomic nervous system will be withdrawn for at least five&#xD;
      half-lives before studies. Patients will undergo a complete history and physical examination,&#xD;
      ECG, routine clinical laboratory analyses and a blood pregnancy test for women of&#xD;
      childbearing potential. Autonomic testing including a posture study with plasma&#xD;
      catecholamines is then performed to determine if they meet the inclusion/exclusion criteria.&#xD;
&#xD;
      Eligible participants will be studied on three separate days in a randomized, double-blind,&#xD;
      crossover fashion. On each testing day, patients will be given one dose of the study&#xD;
      medication (either pyridostigmine, galantamine or placebo pill), and then will have two tilt&#xD;
      table tests (a motorized table with a footboard that moves to an upright position): one with&#xD;
      the vagal stimulation and one with sham electrical stimulation. Heart rhythm, blood pressure&#xD;
      and the amount of fluid in the body (body impedance) will be monitored during studies. Blood&#xD;
      samples (up to a total of 2 tablespoons per study day) will also be collected. The order of&#xD;
      the study days and tilt tests will be decided at random, like the toss of a coin. Each study&#xD;
      day will last about 5 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators will be blinded to the study drugs (placebo, galantamine, pyridostigmine). Participants will be blinded to the vagal stimulation (stimulation vs. sham).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>High frequency variability of heart rate</measure>
    <time_frame>Up to 15 min of head up tilt</time_frame>
    <description>Average of high frequency variability of heart rate during the head up tilt</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo pill with vagal/sham stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine with vagal/sham stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine with vagal/sham stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo sugar pill</intervention_name>
    <description>placebo single oral dose</description>
    <arm_group_label>Placebo pill with vagal/sham stimulation</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine Pill</intervention_name>
    <description>pyridostigmine bromide 30 mg single oral dose</description>
    <arm_group_label>Pyridostigmine with vagal/sham stimulation</arm_group_label>
    <other_name>pyridostigmine bromide</other_name>
    <other_name>Mestinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine Pill</intervention_name>
    <description>Galantamine hydrobromide 8mg single oral dose</description>
    <arm_group_label>Galantamine with vagal/sham stimulation</arm_group_label>
    <other_name>Galantamine hydrobromide</other_name>
    <other_name>Razadyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagal stimulation</intervention_name>
    <description>Vagal stimulation will be given at 50 Hz during the tilt table tests</description>
    <arm_group_label>Galantamine with vagal/sham stimulation</arm_group_label>
    <arm_group_label>Placebo pill with vagal/sham stimulation</arm_group_label>
    <arm_group_label>Pyridostigmine with vagal/sham stimulation</arm_group_label>
    <other_name>Transcutaneous vagal nerve stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham vagal stimulation</intervention_name>
    <description>Sham vagal stimulation will be given at 0.01 mA during the tilt table tests</description>
    <arm_group_label>Galantamine with vagal/sham stimulation</arm_group_label>
    <arm_group_label>Placebo pill with vagal/sham stimulation</arm_group_label>
    <arm_group_label>Pyridostigmine with vagal/sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects of 18-45 years, with Postural Tachycardia Syndrome (POTS) as defined&#xD;
             by a heart rate increase â‰¥30 bpm from supine within 10 min of standing or head-up tilt&#xD;
             in the absence of orthostatic hypotension, with chronic symptoms (&gt; 6 months), and in&#xD;
             the absence of other acute cause of orthostatic tachycardia.&#xD;
&#xD;
          -  Subjects able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Medical conditions that can explain postural tachycardia (e.g., dehydration,&#xD;
             medications).&#xD;
&#xD;
          -  Patients who are bedridden or chair-ridden&#xD;
&#xD;
          -  Subjects taking any medication known to affect autonomic function or inflammatory&#xD;
             markers (e.g. corticosteroids) who could not discontinue them before study&#xD;
             participation.&#xD;
&#xD;
          -  Conditions associated with chronic inflammatory processes which in the investigator's&#xD;
             opinion would affect the interpretation of the results. Examples may include smoking,&#xD;
             diabetes, BMI&gt;30 kg/m2, current infections or cancer.&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the subject from&#xD;
             completing the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Autonomic Dysfunction Center/ Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>vagal stimulation</keyword>
  <keyword>POTS</keyword>
  <keyword>galantamine</keyword>
  <keyword>pyridostigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

